Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-056616
Filing Date
2021-11-12
Accepted
2021-11-12 12:17:01
Documents
47
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q etnb-10q_20210930.htm   iXBRL 10-Q 2463817
2 EX-10.1 etnb-ex101_191.htm EX-10.1 25490
3 EX-31.1 etnb-ex311_8.htm EX-31.1 20143
4 EX-31.2 etnb-ex312_6.htm EX-31.2 20171
5 EX-32 etnb-ex32_7.htm EX-32 15947
  Complete submission text file 0001564590-21-056616.txt   6914683

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA etnb-20210930.xsd EX-101.SCH 31668
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE etnb-20210930_cal.xml EX-101.CAL 34027
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE etnb-20210930_def.xml EX-101.DEF 127343
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20210930_lab.xml EX-101.LAB 311346
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20210930_pre.xml EX-101.PRE 218281
11 EXTRACTED XBRL INSTANCE DOCUMENT etnb-10q_20210930_htm.xml XML 1195705
Mailing Address 535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105
Business Address 535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105 4155004614
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39122 | Film No.: 211401860
SIC: 2834 Pharmaceutical Preparations